
Opinion|Videos|July 23, 2024
Private Label Biosimilars
The expert panel discusses the greater potential for private label biosimilars.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Some healthcare companies are investigating the potential for private label biosimilars, including products like adalimumab. What is the value of offering a private label biosimilar to patients? What are some of the challenges that may arise?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
3
Value-Based Care Interventions and Management of CKD Progression
4
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
5